REGENXBIO任命Greg Ciongoli为董事并同步两名董事退休

----- 0001193125-26-365287-index-headers.html -----
<SEC-DOCUMENT>0001193125-26-365287-index.html : 20260825
<SEC-HEADER>0001193125-26-365287.hdr.sgml : 20260825
<ACCEPTANCE-DATETIME>20260825165706
ACCESSION NUMBER: 0001193125-26-365287
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 11
CONFORMED PERIOD OF REPORT: 20260825
ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260825
DATE AS OF CHANGE: 20260825
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
EIN: 471851754
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 261316620
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>rgnx-20260825.htm
<DESCRIPTION>8-K
<TEXT>
Document 1 - file: rgnx-20260825.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rgnx-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
Document 2 - file: rgnx-ex99_1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img101737798_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 3 - file: img101737798_0.jpg
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>rgnx-20260825.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
Document 4 - file: rgnx-20260825.xsd
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 6 - file: R1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 7 - file: report.css
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 8 - file: Show.js
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 10 - file: FilingSummary.html
Document 10 - RAW XML: FilingSummary.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 12 - file: MetaLinks.json
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>13
<FILENAME>0001193125-26-365287-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 13 - file: 0001193125-26-365287-xbrl.zip
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>rgnx-20260825_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 14 - file: rgnx-20260825_htm.html
Document 14 - RAW XML: rgnx-20260825_htm.xml
</DOCUMENT>
</SEC-DOCUMENT>

----- 0001193125-26-365287.txt -----
0001193125-26-365287.txt : 20260825
0001193125-26-365287.hdr.sgml : 20260825
20260825165706
ACCESSION NUMBER: 0001193125-26-365287
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 11
CONFORMED PERIOD OF REPORT: 20260825
ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260825
DATE AS OF CHANGE: 20260825
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
EIN: 471851754
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 261316620
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
8-K
1
rgnx-20260825.htm
8-K
8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 25, 2026
REGENXBIO Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37553
47-1851754
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
9804 Medical Center Drive
Rockville
,
Maryland
20850
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code:
(
240
)
552-8181
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
RGNX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 25, 2026, the Board of Directors (the “Board”) of REGENXBIO Inc. (the “Company”), elected Gregory Ciongoli as a Class II director of the Company effective immediately. Mr. Ciongoli’s initial term will expire at the Company’s 2029 annual meeting of stockholders. The Board has determined that Mr. Ciongoli is an independent director in accordance with applicable rules of the U.S. Securities and Exchange Commission (the “SEC”) and the Nasdaq Global Select Market. The Board also appointed Mr. Ciongoli as a member of the Audit Committee and Nominating and Corporate Governance Committee.
Pursuant to the Company’s compensation program for non-employee directors, Mr. Ciongoli was granted an initial equity award with an aggregate grant date fair value of $550,000, of which 75% was in the form of a non-statutory stock option and 25% was in the form of restricted stock units (“RSUs”), in each case rounded down to the nearest whole share. The exercise price per share for the option was $8.91. The option will vest in over a three-year period, with one-third of the option vesting on the first anniversary of the grant date and the remaining portion of the option vesting in equal monthly installments over the twenty-four months thereafter and the RSUs will vest over a three-year period, with one-third of the aggregate number of shares subject to the RSU award vesting on each of the first, second and third anniversaries of the grant date, except that in the event of a change of control of the Company or death, the option and RSUs will accelerate and become immediately exercisable and immediately vest, respectively. Mr. Ciongoli will also receive a $45,000 annual retainer for his service on the Board and additional $10,000 and $5,000 annual retainers for his service on the Audit Committee and Nominating and Corporate Governance Committee, respectively. Mr. Ciongoli will be eligible to receive annual equity awards upon the conclusion of each annual meeting of stockholders beginning in 2027. Mr. Ciongoli will also be entitled to indemnification pursuant to the Company’s standard form of director indemnification agreement. There are no arrangements or understandings between Mr. Ciongoli and any other person pursuant to which Mr. Ciongoli was elected as a director, and neither Mr. Ciongoli nor any of his immediate family members is a party, either directly or indirectly, to any transaction that would be required to be reported under Item 404(a) of Regulation S-K. A copy of the Company’s press release announcing the election of Mr. Ciongoli is attached hereto as Exhibit 99.1 and incorporated herein by reference.
On August 25, 2026, the Board also accepted the resignation of Jean Bennett, M.D., Ph.D. and A.N. “Jerry” Karabelas, Ph.D. from their positions as directors of the Company, effective August 25, 2026. Dr. Bennett and Dr. Karabelas will serve as advisors to the Company to assist the Board until February 2027, unless further extended. In connection with the resignations of Drs. Bennett and Karabelas and the election of Mr. Ciongoli, the Board reduced its size to nine directors, effective immediately.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press release dated August 25, 2026.
104
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
REGENXBIO Inc.
Date:
August 25, 2026
By:
/s/ Patrick J. Christmas II
Patrick J. Christmas II
Executive Vice President, Chief Strategy & Legal Officer
EX-99.1
2
rgnx-ex99_1.htm
EX-99.1
EX-99.1
EXHIBIT 99.1
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
ROCKVILLE, Md.,
August 25, 2026 – REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr. Ciongoli joins the Board as REGENXBIO prepares to become a global commercial organization. Mr. Ciongoli has extensive experience in biotechnology investing, capital allocation and corporate strategy to support the Company's next phase of growth.
Concurrent with Mr. Ciongoli's appointment and following years of distinguished service, Jerry Karabelas, Ph.D., who served as an independent director since 2015, and Jean Bennett, M.D., Ph.D., who served as an independent director since 2021, are retiring from the Board.
“As REGENXBIO enters its next phase of growth, the Board has continued its strategic succession planning process to ensure the Company benefits from a complementary mix of scientific, clinical, commercial and capital markets expertise,” said Curran Simpson, President and Chief Executive Officer of REGENXBIO. “Greg brings a combination of financial and strategic expertise that will strengthen our Board as we advance our late-stage portfolio and continue our work to create life-changing treatments for patients and long-term value for our shareholders.”
“We are grateful to Jerry and Jean for their exceptional service and meaningful contributions to REGENXBIO. Their leadership, insight, and commitment have helped shape the Company through a pivotal period of growth and innovation. As valued members of our Board, they have provided thoughtful guidance and steadfast support, leaving a lasting impact on REGENXBIO. We thank them for their many contributions and wish them every success in the future,” said Ken Mills, Chairman of the Board.
“I am pleased to join REGENXBIO's Board during this exciting and transformational time for the Company,” said Mr. Ciongoli. “REGENXBIO has established a leadership position in gene therapy with a differentiated platform and compelling pipeline of potential first- and best-in-class medicines. I look forward to working with the Board and management team to help advance the Company's mission and strategic objectives.”
Mr. Ciongoli is the Founder and Managing Partner of Adiumentum Capital Management, an investment firm that works closely with organizations on capital structure optimization and asset allocation strategy. Prior to founding Adiumentum, Mr. Ciongoli spent over 16 years at The Baupost Group, where he served as Partner, Public Group Investing and led investments in public and private companies across multiple industries and geographies. Over the course of his career, he has focused extensively on healthcare investments, corporate governance, and strategic transformation across both public and private markets. Mr. Ciongoli currently serves as Board Chairman of Atara Biotherapeutics and is also a Board member at Zymeworks Inc. His prior board member and observer experience also includes Idenix Pharmaceuticals, Intarcia Therapeutics, Keryx Pharmaceuticals, Orexigen Therapeutics, Translate Bio, and others. Mr. Ciongoli received his MBA from Harvard Business School and BA from Princeton University’s School of Public and International Affairs.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie, and RGX-121(clemidsogene lanparvovec) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA
®
. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit
www.REGENXBIO.com
.
FORWARD-LOOKING STATEMENTS
This press release includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipate," "assume," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would" or by variations of such words or by similar expressions. The forward-looking statements include statements relating to, among other things, REGENXBIO's future operations, clinical trials, costs and cash flow. REGENXBIO has based these forward-looking statements on its current expectations and assumptions and analyses made by REGENXBIO in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors REGENXBIO believes are appropriate under the circumstances. However, whether actual results and developments will conform with REGENXBIO's expectations and predictions is subject to a number of risks and uncertainties, FDA’s review process, the success of clinical trials conducted by REGENXBIO, the ability to obtain and maintain regulatory approval of product candidates, and other factors, many of which are beyond the control of REGENXBIO. Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on Form 10-K for the year ended December 31, 2025, and comparable "risk factors" sections of REGENXBIO's Quarterly Reports on Form 10-Q and other filings, which have been filed with the SEC and are available on the SEC's website at
WWW.SEC.GOV
. All of the forward-looking statements made in this press release are expressly qualified by the cautionary statements contained or referred to herein. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on REGENXBIO or its businesses or operations. Such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to rely too heavily on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this press release. Except as required by law, REGENXBIO does not undertake any obligation, and specifically declines any obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Zolgensma
®
is a registered trademark of Novartis Gene Therapies. All other trademarks referenced herein are registered trademarks of REGENXBIO.
CONTACTS:
Dana Cormack
Corporate Communications
Dcormack@regenxbio.com
George E. MacDougall
Investor Relations
IR@regenxbio.com
GRAPHIC
3
img101737798_0.jpg
GRAPHIC
begin 644 img101737798_0.jpg
M_]C_X 02D9)1@ ! 0$ W #< #_VP!# (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P 1" !5 >8# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B
7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]^%.113L[
M$ZUY[\0/V@]!\ W_ -CD:XOKI6 DBM@&,><_>)( Z=,YY'&*THX>=67+!-OR
M.?$8JE0CS5)**\RO\;?VC-!^!AL5U);JXN-09O*M[1%:3:OWG.YE4 $@
(?M;_\ !3#PS\"OV2?$'Q"TE5N-
4KJI^:,(DD
MQVL-R0NH8,"!E?M)W.F_'36['4-+:XT_4+6(V[K?;1#,A;*@,K,%8,S9+87!
MY(V@'Y;_ ."LW[+&N>#?V!UU+;:WEU:^*+'6-0C@G4K!:);W5NK*#AG82W:!
MMFX!3GH&:OK
A*5*-=M2E))IZ75]?E8_-\TX@Q/-4]BDX)-II7MIH[][G
MYN_'C]I#QU^T[XNDU[QYXHU;Q-?;V:$7,O\ H]F&QN6&%<1PJ=JY6-5!(R
^MWZG[O_ +9'_!3:/X8PZ+I_@"/2
M]
6NDW&DZM
?#O1-)\,^,XK)'D&B:C:VBV['.P!K=OLS*LB%E+1N,C*@I\$/@EJ/
MQ#\56\U];W5CX=T^X1M2OGC95ACW E$)!W2N 0J]<\G"ABOY10R/*WELMG.V
MK>Z?2R_+N3B.*,[6;Q;O&FFM%LTGN_*VY^VUG=+=*K+_ !
),-C$H*:YNVU_3
MN>G Y%% .117DGTP4444 %%&:,T %%&:* "BBC- !11FC- !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%&:,T %%&:,T %%%% !1110 449HS
M0 4444 %%%% !1110 4444 %%%% !111F@ HHHH X;XN^+IO!?PZU*^AW?:(
M8PD;#&49V"*>01\I8'GKBODR:5YY&D9FD>0EB6.68GDDGUK!^.G_ 4 \<:Q
M_P %$;[X Q_#VXNO"]]]GLTU2+?YP=K:.Z%V6*[/)C<[77/W49@=WRUT5U93
M6%S);W$
_VG?@S\%/#?\ PC?C[QA-IOBC4+A;R*UL
M+1KZ:P6)2$$Z("8Q(LS8!() !_A(KVJT93E%4XMRO;1-NST=K7Z7U^[4^;C?
MV
4=+ZNRNMK_Y'SQ9_\$=_ _[1_C_5E\(^(-2\![E:[BTJXB&I6Z*9/F"3
M%D=54.JJK!CA
9_MI?LHV__ 27U_P/JWA75I/%'BS6I+V>VUS4+",6
MNCF VX3R("71KE6=CYDA8*K J@<*Z?0FM_M%^&=2_9WU+Q)\*_'"ZIK%U=1:
M9J:V\#VUUI-K*)29-C .IDDA1 ^!@$@')!'(_LI:7)^T=\>-!\'^,+6;QMX?
MUJ24WECJ4KSJFU&E,RLS;HV$B(Q9"I8#:
*/
M$5VGB:XTHRPQZ_+'MDBN5C9V*H/M,R%4^7>KG R /7/VA/[6LO ?A>/5&N?)
MN+F[FA64G,B!8=C-GDD%Y=N>S<<8KY[^)W[,GQ5\"_M5-I?A/0=4TO['?R?\
M(R^GQ^59V=EYF8]C*-BQJKCS,]6,A;
YLDJ!7S;J4WB(5:#4HN\FDT
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M^;#;O(FX C(W*,C(R,\BO)S+(L5@JL:5=6
Z>VS/2R[/J&*I2J4G=1W5M
M5\CT;=1O'^S^=?@XW_!PQ^T$[_\ ,B_^"I__ ([3?^(A;]H3/_,B_P#@ID_^
M/5Z5/A/%RCS)Q^]'#+BVA%VY9?
DWJO\ %7X-_P#$0K^T%_U(W_@I
MD_\ CU+_ ,1#7[07]WP+_P""F3_X]52X/Q25[Q^\C_6ZBW91E]S/WBE?Y=RT
MWS,?[U>0_L._&76/V@OV2? /C3Q!]E76/$6E1WEY]GC,<6]B<[5).!QZFOB'
M_@HU_P %V]6_9X^.?B#X>_#O0-)U*X\-R+:WFL7LYDB%SM#21)&O78S!&+,"
M'1QC'->1@
^NBL[-W['JXW/*&&H1JU'92M;35W5[6/U"HK\
M&V_X.%_V@BO_ #(__@KD_P#CM'_$0O\ M!?WO __ (*9?_CM>[_J5CO[OWGD
M_P"N>%[2^X_>%9L_Q4&4$_>K\'$_X.%_V@,_\R/_ ."J3_X[77?"7_@XX^*'
MA[7H6\7>&_#?B#3=X$ZV*/93(I(W%
C;6&1V/%?D'^TU_P78^.GPK_:/^(7A72U\&_P!E^&?$NI:39^?I
M;O)Y,%U)$F]A* 6V(,G R<\=J\' Y55Q-1TXV4H[INUM;'K8S.J>'IQG*[4M
MFE>^ES]L _%!?'I7X,_\1#'[07_4B_\ @KD_^.TW_B(9_:"_ZD?_ ,%,G_QZ
MO:_U1QG>/_@2/+_UPPW\LON/WC296]J0."./QK\'1_P<-?'X?]"/_P""J3_X
M[7Z2?\$
*O&RZ3_:FF^))M)@_L^W:WC\E;2TE&Y2S9;?,^
M3GIMXXR?-S#(ZN$I>UJ
AEN?TL5/V<$[V;U5MC[ CD\RC/^17Y
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M9]N8(O)2TM)1N4LWS;YGYSTQQQFO3J91B(818UI
+3SBC/%O"1
MOS)7>FG0^O6X6DSY2_WFKYG_ ."@OC[XO?"/PQ#XG^'_ /9>H:381$ZI8S6;
M2W$:@DF9"&&Y0OWE RNW=R,X^2_@I_P6-\:0?$>S_P"$VM]+N/#=P3%<-8V[
M1S6N2,2C+-N YRO!(.1R #\5C,^HX6JJ-:\7*UFUIKUN?HN4\&XW,<++%86T
ME&]TFKJWEN?J6C-N_O+WH$F6_I7.>!/B#IGQ#\+6>K:7>0WEGJ$2S13PN'C=
M& (8$>HKC?VGOVF_#O[,?P[NM
%A\KQ-7$+"QBW-NR26M[[6/5%E\QO]JI(SN2ORO^'/
M_!3GXZ?&SXGV^A^%=/\ #\EUJEP?L\/V2206L1.
CGG#N(RJ48XAI2DK\J=VO5=#H@^3_.DC=0O^U7QM_P56_X*:ZI_P $
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M;WVGWEZ]M=Y5M,^R12O
+2D[)W3
M5^VAW8'B3"XJ3C3E=I7:LT['TGO:BOFCQS^WYX>^$5YJ$GC6XM=+T&SF@M!J
M5@QNHUNY8WD2$[DPV](Y6#1E@IA7CMEC
-S]H[X,Z3\)O'GE_\)1X7TFS
MU2X4VMKJ%\EK-$)"P50I.2F0X#=,+@G(->4_M,MX+^'/PRU;P7XPM[CQ)>?$
M+0]ZR:7,C0V%NTH>"='.5D
[;NFWLK>;/._V8_P#@M%I?B_XM6.AZU\,[6U;7,V>F
M7%O?O=R"^?Y8$=651Y;N54GDJ64] :_-OQ-XJU#QOXGU#6M8O+C4-6U:X>ZN
M[F<[I)Y78LS,?4L>?RXQ7UMX9_9M\#_L,6_PU^-7C3Q!<>+M/OM1:^\/^&].
M@-K>7-U:3+N,\CY010R!=VT?.=H'RL<=!X2_X)V^'?\ @HY9^(OB-\%=6M_!
M]FNHLFI>%]9QNTF9SOS#,ORFW=3O4$94[E'W03]1E>88#+L0Z_*^222
NM._;1^&]G;QQW5KXB
M\06>@ZC;2J7BO+.ZG2&='4=0%
6'4IT(P0?LW?\$E;?\ 8>^$GCCXK:MX
MFL?$GC[P_P"']0ET7[#&#;:-*;5L3\Y+3*?,4'[H&".:^-SRV:_GOQKXZE/%
M1I8&3C&2M)IM7L^B^>Y_7GT>/"W!8JC/'8^$9RI_"FD[.U[M_(]R^(/[1OQM
M^%GBBWFU+QIXDAFOH4N+6Y\T&&YC95;
E==X/^.VD_MI> _%
M7PU\>0Z#X?\ ''C:R6PTCQK!9)#<-< ILAN74;RDK+Y;L#\Z2,I&"!7U)X^_
M9AT/X_?L8:&FH26]A?:7IL%S:WS@#[.ZQ*223_"P&&&>G/4"OS!NX9-&U:1(
M[B.1[64J)X)"58JV R-P<'&0>#WK\=HYUF&38RE5C4
*I/%'C"WT.X\3>*M'OM
M)T+28[D7EK
)Z)^W!\4/"6C2:7H_BJ;2]'
M:=YO[.MK2!;/<[;B3&4*L
,7^!?Q.U*/=I?B
MKP+:6;N@)2&]C=YI0>,+O6ZCV\Y;8^/NFO@]@ *_O;@&GALSRZ.,KQC*
^'
M&L>,/^"C/A/5M.M9)-/\(V=]?:I/@[((I+2>V0$]-S23IA>I 8C[IQ_0#MW0
M_A7Y!QS@2^9^
MW5X=_P"Q(M/_ $OOZ]L_X(&>%?AWKO[*WB:;Q=IO@^ZU"/Q=<)$^K06TDPB^
MQ66 ID!;;N+X XR6[YKQ+_@XZX_;G\._]B5:?^E]_7AO[(7_ 3;^+7[97@*
M_P#$G@%-);2=/U%]+G^TZE]E;SEBAD;"X.1LF7GUR.U?:X7 T:W#M.-6JJ:O
M>[[ZZ;H^$Q&(J4LXG*$.=W>B^6I^Y0^'GP(<_P#(%^&?X6ME_A5'7? 'P+.D
MS?\ $I^&,>X%23;62]>V<5^%O[77[$/Q6_8FN=)7QU9R6]KK2-]EOK.\:YM7
M=2
GV^K:PYCM1JE]]GMY
MI.H3<01O;/R@]3QWKGPO!:JT?K-/%
'V#:%'J=TNG%22#:B5O*(SU^3;7]1-TMC+X4F75%M6TMK4
MBZ%T%,#0[3O#[OEV[
*_'?]EO_ (-Z/B!X@^)&GS?$[4-'TGPK9SI+
M>6^G77VBYU"-3DQ*P $>X_*6.<#<1SBOUD_:2^']]\2_V
\/
M7VF68E?9&TLUO)&FYOX1N89/85X7&F9X?%5J-&A/FY%9R6W3_(]SA#+Z]&E4
MK3BTY;)[OK;T.0NO"GP")_Y!_P *?^_%A_A3!X6^ 9_YAOPI_P"_%A_A7Y$R
M?\&_?[1"?\PWPI_X.!_\10?^" /[1$G_ ##?"?\ X.!_\37+3RW".*OBE_7S
M-:F,Q'/_ ']W_ /UV/A;X _] WX4_\ ?BP_PIR>%O@#G_D&_"G_ +\6'^%?
MD-_Q#]_M#_\ 0.\*_P#@X'_Q%'_$/W^T/_T#O"O_ (.!_P#$5J\JP5O][7]?
M,(XVO_T#O[O^ ?NCX:M='M?"]G'X?73X]&CB M%T]4%L$[; GR[?IQ7\T_[<
MCM+^VK\9&;_H>-;Z^@OYP*_H0_8B^$>M?L^?L>>!?!WB".WCUSP_I$=G>""0
M21B5
\(^#]TW@W2+F\OKS3X!
MN=K.%F=W8=2QR23R37;2_#W]G
37/$'PYT>UM5N)?*B+_ &2W;YG[# /-?F_-_P $ /VAH_\ F&^$_P#P
M<#_XFO*P\8UZE1U\0X-2:2;>J[[G7).C1I^RIJ:<4VTMGV/UJE\ ?L^*-O\
M9?PKV^HCL:_/O]L/_@D=I/Q\_:4\3>+/"/Q0^&/AGP[K$D#6>F^>J?9!';Q1
MN,1G8-SH[
M>
M!_%"VL>O:"\2W:6THFB!DB29-K #=\CKGT/%?49+E5Y2^J8KFE9W2UTTULV?
M/9GC6DO;4>57T>VO:Z1_1;^Q%\*KCX&?LG^!_!\VL6/B"30=.6U_M"RD+V]R
M S$%&/5<$*/3'M3/%'AWX&WNNWTFK:?\,VU1KAVO&NHK$W!FW'>9-PW;]V=V
M>
[DD0LNWABC+D=CQ7Q&&P<*F-J4JU50Y6_>>EW?7J
M?9UL14A@Z
U
M_96#_P"@Q?U\SR?KE?\ Z!OZ^X_7JV\)? +=_P @_P"$^/7R+#_"O0?A#8>#
M]/\ #-Q'X)B\.PZ6UPS2C1DA6W,VU
O(S; T*-+FIUU4=UHOSW/4RC$5*DTITG!6>OZ'YX_\
M'%"L_P"W;I/_ &)]G_Z57M?'>K_"OQA\// _A/QXUCJ&GZ'X@>:XT;6("RHL
MUM.\+@.O*2QO$2!D-C:P]OL+_@XJE_XSRTG_ +%"R_\ 2J]K[D_X)+_!;PW\
M=O\ @DKX#\.^+-'L=
M@ X*'Y2,8P5%>#F7#6&S&D\;E+3;UE#SZV73T/=RWB'%8"LL/CT[;*3_ OW
M1]'_ /!SG/YFN_!MO^F.L_\ H5C7K?\ P;73%_V-_%W]W_A-;O\ ](+"OFG_
M (+O_M%>$?VH?"7P/\7>#=2M]4TG4+;63E2/,A?=8@QR+U212""I].,@@GZ;
M_P"#:R39^QGXN_['>[_](;"L
$I[_QQX#L?^)>Q,^I:9"G^
MI[M+$H_A[LHZ=1QD#].$W%LUYO\ M#?%WPS\*/ACJ6J>(;R&WL[>,[M_+2D]
M%5>[-T [_3FOQ#B#+J&)P\E6T4;M/JGWN?O_ ;GF,R_&P>$O+F:3BKM--[-
M'Y;?L+_MVWO[-.I2:+K$EU>>%+[<_E\R-82_WD']UL?,HZDY'.<\Y\8?BEXR
M_;Z^/-O;Z?9W%Q)=2K!&S':PYRS.WW1Q\S-T'3L*X'XDZS#\8/BYJU]X=
MT-K&WUBY>:TTVV0R&-5&YB%4?>(5F8 8!+8P!7;_ +$_[34/[,WQ5_M"\LH;
MK2=2"6]](L>ZXME#9$D9[@%LL/X@!W45^/8?,J]6M#!XF3]DI6YE?5+;5]#^
MJLPX=P>&PL\XP=)?6903Y6T^5M:NRZGZ7?L-?L/Z/^R=X&69ECU#Q-J2*U_?
M%?F)QGRDSR(U/0=2>3V ^C?]6OR_C7'_ M^(&D_$OP/9ZQH]Y#?:??1K)#+
M%(&5E/3']0>000>178(,K^%?NF6T*-&C&-%)1MHEM;O?JV?QYGF,Q>(Q4ZF+
M;
_:W2Q^2O_ <]G?-\%?KK?\K"LK_@WE^&7A7QYX#^)$GB30]!UB2U
MU*S6W;4+*&X,:F*0L%WJ2 3R<=>*U/\ @YY.RY^"N/76_P"5A7Q7^Q#^QC\9
M/VJ](\077PMU!;&UT6XBAU '67T_<[JS(<+][Y5/)Z5^[Y1A:=;AA0J5%33D
M_>>RL[_CL?S_ )M6FL]DXQ
/!_P .OVT[.U\&Z;H^EV=Y
MX9MKJ^@TX(L8NC
X(-?C=\9O@?XB_8I_:,M]-^,WAN'Q5J$UI%J?V9]6D
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M][/T1Y+A/Y(_
\1_
M\$_=)^)^@ZMIWC[0_#)T74M9&N-HFCK+]A%ZMI#:I<*2JF-A''(K(H*L9"Q.
M[.2OJ2BOSCZW4/T;^R:'8_F]_P""K./M2WDFJ2MI9D!\M],
M!Q9F/MM\D(#MXWA\_-NKVS]E?3O#,W[%VFW'Q*U#Q!'XBM]5N$\.06[J\TNC
MM%$T:_/D1P?:3<,A(R"Y*@HP-?L1\:?@9X)^*5I'=>)_#.BZ])IX,L#WEHDS
M0[
\YM2
QZ5\?/'
M/PA_:8^#7A'P'J?A?Q)X;T_PC<2OINK6=W'<75JD[!KC
/P-\:;K0]4'VC0?$5E
(Q,:-9*TDDI)6:M9):
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M?XB0/
_9Y_9KUV.^\4>)O$#1W2B6WT*TE$DTR;@I(P X7DG+. =K
M8R017;? 7]M/]GOX8:')X5\(V.J>$X;Z)XFU&[M%Y?81O>0,S%N ,D'G';)K
M\YP/AKFV-Q$,1B(MPC;9-JRZ+R/V7,/'KAC)
G[1?
M_!)#X6_ O0M/\0+\1O$EYH^K3-!;Z=%90_;G91EQN^ZJJ"N6(/WEX.
35]/?3+)9FL;9U:'S9%=EW)+-#MV*0V(2V0 -W]#9#[3*Z<:=*K)0;]Y+
M5M);I.]K>70_C3B/&/-J\JT5&4WK%O1)M]7?6Y]*_P#!(_X:?"WP)\"IF^&]
MC>6\DDZ0:S
,_L<_LJ:;^RK\.I-
M'T^ZN-0FU"X^V7EU* IDD**N% Z* HP.3R
[C,ZHU,GIX*+?-%W:L[??L>'@>'ZU/-98
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M2IT
M+O\ P4C_ ..5P7_$-#\-O^A^\
\@FMYF\9:M.$D0J2DEW))&V#V:-U8'H00
M1P:_HJ_9T^!=C^S;\$/#/@73;R\U"Q\,V2V,-Q<[?.E5>0S;0%SSV %>#_MH
M_P#!(#X4_MJ>-+KQ-JT>J>'?%EU'%'<:II
_!^I:7XHFU'POX=T[2KEXK13&TL%M'$Q4EN5W*<5WX_P"#C+X.
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M-KI]C;QVMG9Q+!##$@5(D4!550. !V KX$^,'_!O;\/?B_P#%;Q1XNO/&
MWC2UNO%6L7>L7$$ M?+ADN)WF94W1$[07(&23@
\7?^"H?_'*X+_B&E^&_P#T/GCK\[7_ .-4O_$-%\-_^A^\=?\ DK_\:KV/
M8\/_ ,\ON_X!X_M,\_E7X'>Q_P#!PQ^S^O7_ (3#_P %2_\ QROH[]C?]M#P
MG^W)\,]0\5>"_P"TO[-TW4GTJ47UN+>3SDBBD;"AFRNV9.<]
UKWZ'Y2
M_P#!Q-S^WAH^Y?F_X1&S_P#2J]K]%O\ @AA"H_X)?_#?_?U7_P!.MY5/]N7_
M ((^>#?V[/C#:^,O$'BCQ1HM]:Z7%I2PZ>(/)=$DED#'>C-N)E(ZXP!WS7N7
M['G[,6F_L<_L^:'\.]'U#4-4TWP^USY-U>!1/+Y]S+
""#@BOR[_ ."G'_!"F/Q'
2:;>PW5G<6,[QRVEPC1O;R@A7#(V"K
MY0!@0#\H!Z
>%_$4
$
M?#^K:QKEGJFKOK$D^H>7YJ2/!!"4'EJHVA8%(XSEC[5]IQ/QAALTP$:48N-2
MZ;5M--[,^/R#A.O@<
E_$_XCZ7\*O!]]KFN74-CI^FQF::
M>8[511_,GH ,DD@ $G%?D)^V=^UQJW[8/Q.CM]/AO(]!MY_(TO3E4M+
:AKVI0J$MC?B,K:'G
E+&5KSJI-1C9V3[MF#
M_P $]/\ @G[IWP9\$KK_ (ELX[KQ5JR9D\P!OL,3<^4GOC&XCJ>.@KQS_@I'
M_P $Y&\/3WWCCP/8L;=MUQJ.GPIU/5I8E'YLHZ]1SD']*;:V^QIL7"JO JMJ
M>FQZG9R0S1^9'(I4@C((/:KQ'#&'J818?EM;9]4^]_,Y\#X@9C1S-Y@YN7,]
M8MNS5]K>70_&W]AO]NG5OV6?$JV-Y)<7W@_4),W=GG
K:QH<>I2^<]I9M%Y,;GEBNY"1N.3C.!GC%>L?L??L7Q_LB
MVFH6>E^*M>U32;X;S87HB\F&7(S*FU058@$$ X/!(R!6?#F#Q^$;I5K2@KI.
MZNK;:;V9W<
3FX^"N[Y>=9_]L*\:
M_P""-O\ P4<^'O["OA7QI9^-EUKSO$5[;3VW]GV8N%VQHZMN)9<'+#'7.:_3
M?_@H+_P3*\,_\%#G\)MXB\0:]H?_ B/VO[/_9PB_?\ VCR=V_S%;IY"XQC[
MQ]J^:S_P;2?#-F^7X@>//?BT_P#C5?O65YWEDLFCE^+DT[MNR?>ZMNC^9,VR
M/'PS*6+PJ3VM=K71)Z';_P#$0_\ /\ N^,/_!2/_CE(W_!Q!\ R/N^,O_!2
M/_CE<7_Q#/\ PW_Z'SQY_P!]6G_QFC_B&<^&O_0^>//^^K3_ .,UYWL>'_\
MGY+[O^ =/_"]_*OP/@?_ (*U?MH^&_VX/VDM-\2>%;74(=%TG1(=+CDO(A%-
M/()IY7;:"=JCS0HY.=I/&0*_5[_@B+:36'_!,/X?K/#)'YC:G(BN"#M;4[HJ
M?H0<@]P0:X?X7?\ !O3\$_ FHQW&M3>(O%S0R"14O;GR8R0<@,L00,.Q!X(Z
MU]R>%?"&F^"/#-CHNCV-OINEZ7;I:VEK"@2*WB0!515' &*>>9YA*F$IX+
M")\D'>[W_ICR;A_$TZT\3B&E*2:LM=7;Y'\U/[=_R_MN?%X?]3GK'_I;-7]
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M-+F"K<28Y
/C_@VB^&K1_P#(_>.MOTM/_C5>_C,ZR;,<
M/26+
3A
.?RM/_C5+_Q#0_#G
M_H?O''Y6G_QFO-]EPY_-+[F=_-G_ &7X'PS_ ,%=/VU?"?[
XAAU#QA=W
M%K(Z%5N8Q9V49=/[R^8CKD?Q(PZ@U6\'?\&WOPCT/6H;C5O$WC37K53EK26>
M*W5_^!1JK#\#7W/\$/@[X=_9^^%VC^#_ KIL.DZ#H8*> A@,'=QB[W:M9:Z>8^'\AQE/&O&8JR;3T3O=NWW'<4
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M:< I([(<].1QFOY\?B#\4_$'Q2\:7WB+7M6N[[6-0E\Z68G8%.T *BKA455
M554!5154 "OUI<1/B"E+#T&X**5V]7Z))[.VI^&X/PSJ9%B8U<0U+5V2;M?
M35NWW(_62YMIK&ZDMYHY(9K=VCDCD!5HV4X*D'D$'@CM70?"SP[>>+/'.FVU
MG#-)Y=PD\SKG]S&C*SN3_#@>O5MH')%9_P#P3D\76/Q+_P""9VJ?$CXK:+J&
MJ-\/_P"U'BU-?,2_UK3[.%9M^\NHF9")8%)8*/("G!#&OC70?^"U?Q(\$?$>
M;4-!T/PGI?A>1C$V@BR\P/%N8J9+IO\ 2'D"M][>$SR$ ^6OGZ-3$8Q3P]""
M
)-6D::\U:
MX:;8[,ZPH?N1+DY"(N% ]!7.KG;72>,O!5QH>G:+KT-C=0^&?%UC'J^AW$I$
MBRV\BAQ$S@!3-%NV2#@AES]UE9N=1&ED554LS$!0!DDGH,5^E97C,!#!15XK
ME232M96W3\^Y^!YK@
\?#OXX^/K7]D;7-'\/W&I1Q
M^%]8M))+NVRTUI93QW#,@< F.,2P(2PQ_K&4G:2*]T_8 ^!=C^V/X5NM8^,7
MA>U\;6.@W<8\-ZCK4'GRMD.MQ$KMDO"I6/Y>5#;NZG'I?_!+_P#90U+X.?"S
M4-6\26
%IU Z45\*?M@48Q110 4444 &**** "BBB@ HHHH ,9HHHH ****
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04 %%%% !1110 4444 ?_V0$!
end
EX-101.SCH
4
rgnx-20260825.xsd
XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
100000 - Document - Document And Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
Cover [Abstract]
Amendment Flag
City Area Code
Document Period End Date
Document Type
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, Postal Zip Code
Entity Address, State or Province
Entity Central Index Key
Entity Emerging Growth Company
Entity File Number
Entity Incorporation, State or Country Code
Entity Information, Former Legal or Registered Name
Entity Registrant Name
Entity Tax Identification Number
Local Phone Number
Pre-commencement Issuer Tender Offer
Pre-commencement Tender Offer
Title of 12(b) Security
Security Exchange Name
Soliciting Material
Trading Symbol
Written Communications
XML
6
R1.htm
IDEA: XBRL DOCUMENT
Document And Entity Information
Aug. 25, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Aug. 25, 2026
Entity Registrant Name
REGENXBIO Inc.
Entity Central Index Key
0001590877
Entity Emerging Growth Company
false
Entity File Number
001-37553
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
47-1851754
Entity Address, Address Line One
9804 Medical Center Drive
Entity Address, City or Town
Rockville
Entity Address, State or Province
MD
Entity Address, Postal Zip Code
20850
City Area Code
240
Local Phone Number
552-8181
Entity Information, Former Legal or Registered Name
N/A
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.0001 per share
Trading Symbol
RGNX
Security Exchange Name
NASDAQ
XML
7
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
8
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
10
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
23
1
false
0
0
false
0
false
false
R1.htm
100000 - Document - Document And Entity Information
Sheet
http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation
Document And Entity Information
Cover
1
false
false
All Reports
Book
All Reports
rgnx-20260825.htm
rgnx-20260825.xsd
http://xbrl.sec.gov/dei/2026
false
false
JSON
12
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"rgnx-20260825.htm": {
"nsprefix": "rgnx",
"nsuri": "http://regenxbio.com/20260825",
"dts": {
"inline": {
"local": [
"rgnx-20260825.htm"
]
},
"schema": {
"local": [
"rgnx-20260825.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
"https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
"https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
"https://xbrl.sec.gov/country/2026/country-2026.xsd",
"https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
"https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
]
}
},
"keyStandard": 23,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2026": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 24,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2026": 23
},
"report": {
"R1": {
"role": "http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation",
"longName": "100000 - Document - Document And Entity Information",
"shortName": "Document And Entity Information",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "C_15282b4e-174a-4c63-a5b3-59f33dce90a1",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"h2",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "rgnx-20260825.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "C_15282b4e-174a-4c63-a5b3-59f33dce90a1",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"span",
"h2",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "rgnx-20260825.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "AmendmentFlag",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CityAreaCode",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Cover [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "DocumentType",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityFileNumber",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityInformationFormerLegalOrRegisteredName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityInformationFormerLegalOrRegisteredName",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Information, Former Legal or Registered Name",
"documentation": "Former Legal or Registered Name of an entity"
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityRegistrantName",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "LocalPhoneNumber",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "Security12bTitle",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SecurityExchangeName",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "SolicitingMaterial",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "TradingSymbol",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2026",
"localname": "WrittenCommunications",
"presentation": [
"http://regenxbio.com/20260825/taxonomy/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r6"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
}
}
}
ZIP
13
0001193125-26-365287-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001193125-26-365287-xbrl.zip
M4$L#!!0 ( "*G&5V4Q=#WIA< 'G" 1
"TR,#(V,#@R-2YH
M=&WM/6ESVSBRG]_\"JSG
U'XE(@TS
M'J?=M[\>G'>.CW_]^[L?]O]&*3G\<'Q"3L05.0B+^%(
7-,.NW"*55
MXQTI&+XGAZP0I&UHAD,UCQKVA>ZT#;-M.TU7L\W_U;2VIDU5RP8C&7=[!=D-
MWQ"L!7VGJ4@2,2(?XI2E8
@(S+^-P<35>R%8Q&H@6%*1I67(,51XO@@E&H+?^_/SI/.R)
M/J/S0^=B#ONY")O=[+(%'UI($).1%!2^S711EYT,I%5(EN91)ON*''&<-A*B
MJ4^ULWAL=S5B&%0SJ#X&1G;3"6*EZ(KT.H@SQ1,(L^89]LZ['\A^3S .?\E^
M$1>)>.?1W_=;Y4]\V1<%4PQ&Q5_#^/+M3B=+"V [>@$HWB%A^?1VIQ#714M1
M;0L;;56M[@<9'Y&\&"7B[
XWNLSV8W3-AL6V=_B_B"3@/%B[S^
M>RZNV]H>O1+!U[B@V"[-X_\(ROB_AWG1UC7MY[U!EL
CH.7Q
M9=T9C_-!PD9(+OAU/[YN(TQ"EC]CSD6J?D[HB<3\[
+?!X8.R1E?>Q%Q.VC%- UZ@ :)$N.$?[?Q:A"S75Q)B)
MVK]TV_",P!)4=RT&C3HF979@4MN/3).'PM>8OO-. T*T?
>YU#!/$XM9C(*3SX5?NCZH<^YKWO3D!Z P.0H-#\DK/LX"".6Y.(&<*U9
ME$H1"0DR7N3O]I'3V[EB+.B(*,YO(W^^W
_ST[7
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MX^3XXNB0G%\<7!R=[P>R]>[\J//'V?'%\=$Y.3@Y)$=_=OYQ
]FCJDR[8%
M6G!=-%\Q5_VL:(B %1WS,7M5590=K/K>8#[I&?
?2:+
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MO-I3;C16 D?_1B^5*:[(X@J HX$4[&M;_9_BB\43>%,6W "L
V91AVX#N6N2Y-_$4YCT>E2[E#RA#3VYWXNFAS>$/[T$L/JU'.
M1G0$PZ(B?58,'PR[0\"C83=4./8^W0PRM57P.7:"'\CTC]+:R[I8KT]OORJ?
M>]TVRJ0KPWJ
K4"G2#,C/BU-&8'1F".TQHJXJ+,NIY)KIQ
MCJ'HX@2^K-6FN'?P#Y_7LZ./1R=_OC\^54LS#Y 7#YAV<[-,4[=Y'QT^'%V[
M1]<,3"F
@STF'RS8LAB65-_*U1?JE#=
M7(/
7V#%/Z+.XSKR'E')NA^\YW(Q /]( V]WS)V7ZF[<*L07ZV'-%;H.
M^I0ZMNN#'K8
9K?=#D; K)L4R9OM+=E&7I!E7<*:6<_7 5_Z>30,F
M#!KI'N?"=H07KAQT+6GF0YP(Z#L0\EGG7]-T:KJV;6X)8"$!&)%A:L(SJ&LR
MEX(9[P,!@/&NZSSP \V--+8FH7'!KH^K]>I0"8YO0 V62W7/UEW;>I0;OT!E
MN=^9QBHM^_53W_/,[ZY21AB^/2UZ0I+?AC+.>:SBNFIQ%AR,&>7U9@/Y_X5/
M02?K]^,
V>OQVPXXER+/JS^?XE3HSVKG^)YFD<^"XT21CD(-.93QY?(A
MG3&5&-\?E6QY^27,TF)>]NV N8;O4N$(BUI!**CG $/KD1D)S;",P&!KY>4.
M_#R5%]G5\\9BS[+PZV6<)/=Q[O-!U'A -HP(#<=R?9]&W !,VS:&2#6?FJ9E
M!9:N<2'6%"*M9D?%,$[E%YE=QFI?V";%TS\S.4I8RE]A.'6YA
T\8G\NF%ONL#:P$S^2>+C+S]ZAN[N
MY>1")&+0@TK5(IHZ[",9(G[(
[^K9$26:PONT2BR36HQ
M)Z">Z[HT\B(ML$.#>4RL:L6A[XIC?WZ[S;K/:GL^6-X\P&_ECF='+ QH:%D^
MF-0.HX'K^E2S0B9T!A3F1ZM.QJ<,^/D+4N@W2.:P;3PJP]/7M"-CJ]*V*NTE
MJ[0E/>Y0>!&S H
7KUKJR1<<'!WV 'T)^$EV6
MG,I2X0DI^#IW
5!L45]ZWT32W^^'NW;"]+)+F]FPO&O)R!TZL#P&=G@B_JCW8;#"0
MV4#&F. '>H$$(LFND-CP(](@\>CO) *5 ]9QG),8F^! A$5&\K@_3 J6BFR8
M)R.2@S#*HY&J657( AAZF3=5[?F6DXU(0VA'$I:.ZF\1:+3L"NMA&#[&9+=\
M)3M\W6@CTR0S=
5'W[6LO?LTU>90784@0/,TALA@ZI"%LR%8
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M9.%9VP^A\ZKL')VO_0PM_QG.T%JCLIS8;W(
*)Z>0Q8V"L/
M1W[&Y(G;IX#\&*E_FKE-W]L2]_+$?2$9#K(\CGG4A]J[SYI-M:7L+64_H=@^
MJ<[ 4E);U%8H&$[0&[R96%??=(/&]Y:C>,N]'(Y@CJ%'U.:.1RT/W#7?TCSJ
MAH8?N-ST=6_E31F5Y3S2C4!I[$=2W,,64L / DHZ+[+P:X. 94PN63(4Y">8
M.TW3R0!OH.B]SI-RO@
>("
6$BRA.RP-6R\59S5YP[/WDM'N3["+_NGN8IFSZ>VJ=
MMJX#O0&A#?"$5DP-*B.L1D"-!YZD/]\V!ETGU:=:;VY2T'DFV^)I+YK8)$(\
MNH6H[KD?!@&X937%#9@66"9,N*WK>!RA3CU7 PGIAD&H<\]UV
8*FN?"/E?74XU:JO9(2=7\70-1)O"@.!+U)
MV,F9Y'F9_L5O6^XP=]EXN6-:VC4?PB++T=-3'.H\&Y-9?!/>!F=*WGW)8)2(
M:\IC6
?8\G?KUY#R%>"1I'H[I758H"?=US06%O'(VI,%Q>K$K5
MG8OE0M;L!VBR?#U@75%&;"B+0.VU67+%1GFU2K.AMR?>88'==TO6TFFI&YZ)
MNU:G:V,6?(\+T2=V4S/^YQ"76 N\,1NDW*%BIDSF*#\[X)
%6JN'+S?KH6X6:
(6VXG3
MN3%.TW'
]#]9^F9.Y>G8;2DN\S4*NSQ+2+[]$?,+0]]5G]UO>49IV]
M:V.F;&73U:4;8Q/A(Y@.2$L=(,9NEL3H!#'201E(CH\)KWJN%7?5#A%1)-0]
M\23N]P7'//1DU"2?97/
T".2-GD8HR?GG+;L''EN14]:'8:CLKI0YH:"$58
MDU$!LZ E(SG>.5Z9/8-! I86JG4)#EM>C_R/YGESVF$#HV=BQDP=\SJ-]?.C
MSGA^L'QQM],_/2J6Y!G"@N( 1C4S(#5%?8%[#,?Y(T,>%R4812&$ZNTD XPP
MA3Y\[%0'_0KR,;L$LE1#'M=HKLZ-WTM(8?H:O$7T&=8R6-G/,NM*UE<&--YZ
M+\HS:,68QO+&[.1=P>QUT5*'655D63('7O%>C @>S\]K^YNP;A?8$Z=,U2!X
M"1B)6%PO5\#D_V3;6@/PT\"'
7(K6J9:QNI(UU?AC"
22H5?5A&K
MX@J>1S3*AK(LF>-KL'S1[!UWBIB?&OBRHYX05SJL18G">$[R8?!O%$O5G$%'
M%6%.H4A-<[T#"%'5(+D )N(5?-C3!'GQ1)!.T-? 95TQ*$J979%=>46?HM=Z
MR3=200Z9)?-:""B#"U;T&M.XQNXGJ 'Q#B)6UI,5 (C]&:55$YZ2^%AD^AN.
MMX$<,"BUW;R.J_I 60W<+E ?,O*392-'UBI,BM)U4(2,4;M
1)0Z2==J]K@P.*+FLMO:V]E57#_@ .8)A#;,:*LF!IZ">&T*,O)<%#!
M!7,8)L.\8@Y%/G
>@&U$5:\0U8!>ZMR$> ,)*5E#O<4&/UT\GAWX-[)'H=
MPAC+O"D#8;8E!CRC#&XE?="&@?]2T-0SIK@L\V=5LP ^C@186J1S:ESQ"E"Q
MBE0#L^9SH);B_(;VJ$TW90;4D#94
@.DQ*_Y_3W)CD 6AF,YIA]/%D#=:@4.-L"=0R0$&@9
MS(DMI<>47W7#""P*(#H B<.1X!1]UX< +?X?E,OF7]\'T)5#B@O&$%O$?P&
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MQ,)SH,[0#=OPU[&=)50KT)BE6
:N6[\>9Q0_8K-98M!&%#Y,1"=DP5\NN<5XE E19 ;B""!]
M)^!R7R!Z+(EPM1T;*A,HR@*X#C],H8YJ#OBKETE &_>N2RR*2=F.8\YD\IZ
M3*7'U+D?NNU)&MO-X5ND;9&V*4BSFN92V1)E^6^ZF#.[,>/A(92M9-W2^Q9I
M6Z1MD?:JCW9;5N,];]3T$'RD]@N@[LW&XMSRZQ:?*^+S_>CIKP)=
P);.4M\H7ASL.OY+
&2[?/OJEC3W6T'&1^]^V&_UBG[R[K]02P,$% @ (J<972^# &"L
M" N6$ !$ !R9VYX+3(P,C8P.#(U+GAS9.U<[6_:.!S^?G^%+_NRZ182
MZ+JM:'3BVO6$KFNKTNFF.YVFD!B(9FS.25KX[\]VXKSA! HE <0^K&GR\^/G
M\5OLIW8^?9Y-$'B$U',)[FC-AJD!B&WBN'C4T;[U]6[_HM?3/I__\NE770>7
M5[T;< .?0-?VW4=XZ7HV(EY (7C=__H&?/_]_AKT[3&<6."2V,$$8A_H8.S[
MT[9A/#T]-9RABSV" I]EYS5L,C& KD?@%Q1:_#ZXM'P(VBVS]5XW/^JMTX?F
M^W;KI'WZH6$VWYW^9IIMTTPE(],Y=4=C'[RVWP">BN6-,40(SL&5BRULNQ8"
M?9GK6]##=@-T$0+W/)D'[J$'Z2-T&B'HS'/:7BC"M^@(^C?6!'I3RX8=+9)"
MX0CBV< E0@+/T_S8.M6 Y?O4'00^O")T<@F'5H#\CA;@_P(+N4,7.JQT$>3%
MD@E(/6;5@;TVQ,&D%>
W>-V%R9F"
M.#$O]:>3*+G9-+Y_O0YK2 8C%__,1*>R,T\,_GA@>5"&!YX^LJQIG&)H>0,1
M'3T0I2&#'>AF57C0;HS(H\$>9 +I",^6EFXDCN$XOJIPS%,C?)@.=4NTL;;H
ML^81:YLME$54
3*ULF 9$
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M$!(RQ' LT5V?)XAALKF*5Z;#7J])MG'&Q,Z$(MZ3"
73#278I
MX7QXI90O6&^A%NJQM\3L3S@OY)J/JY3D%[;8&[&%^1^4//GC"S*96KB8JCJZ
M4L)7+H(WP60 :2'+5$BEU'K8)I3-X,4<132]"Q*PNIV7]JWR5!4+B*=8W$N
M]!J.+'1+[^'(]7Q(H<-MBQ(E*R6O5%*8-[6P7TH]%U8IQ0=KUG/8&. .W7#%
MMZ1Y%\571)JO2]'=F.#B;K@04A&U.\KZSH3-4FSAA_4\+X#T@4_3Z>UPJ*2Z
M-$D]U)]%N@:Z?6@'E+7%9FOPP)=)"I(+(153^S*SQQ8>P8)^KPRKBB)!KLV6
M\GCTE0WWU+60BN!B4$7T'JC%O?K^?#(@*F;9YQ61^HM5%EMQ\W8?X&C@\Q3D
MU'$JDCP--VG9%?_#!,3ZMWYVC<^FD"2@RFEF9KW] PWB
XVKG /](
ME'\C^T8\?6F^F:7XFGQC#,!!MLDVO4A?MW"YN<
X.BV)#?!"2D3[)Q1P
MR,I49 R"%Q(28@(&NO6>7.8=O) :@
)N7T_.7]A,2 0&!!I@<-OGKS0=
M-E,A(4&("2+0[6M)K(G-!' <$ )MGW2I0[&9C@QTJG=$&534XU
<]3LV4Y9@542^P #93 4#!5G4"OI7WBA94X* 0*G
M M+++),U13!8W4[A@A 8A,A 0%
DHF2#RF9J'9TR.Q(D?U4Y'!5056Y
M#T12772>ZJ2JVAT2%VK>=:J3:.F>$
KIG21YQK'95"?1I?M+).MR
MVVEG)"SN.E$*R'E-.T-?N1=%J6#19]H9$04[5)0R5!93_4(*]JUD%:A,I?JI
ME^YFR0HH=I7JE[&XQR7+/>
^2
MR0I26$;U$U^R=R:KH,PWJE-*T8X:R5[I$M5)>-5]-E+ 2H[1#@E:7
SQ<=SQ<=SQ<=SQ<=SQ<=SQ<=SQ<=SQ<5.A%%&U+V]GQ1>GG_
M(J;)U*(,3[?'+G*>N5TDMY FE/7GCM8TS:;)O_ U9
7>1Z)SWU\3!89)TB/?'83 K,ED7EZ$#+3%DVB[?U!:%OB
M\21R/QR(W-4
-DGK=]YGK$L\I$?IQSX4N^E1)(]WWU\ERHRO1
MNN^3V3)G+%&Y[ZUUT5"+M;7V?7:G=N1B?2?[WAM5=E[2,O=](I!S Y-FN>^+
MJP)',:FYY\Q8HXU,^3U#N2\_\__X-Y[#VY^,W*>\HQNI#WZ'=\(/CI__#U!+
M P04 " BIQE=S,OXW+X0 $2 #P ')G;G@M97@Y.5\Q+FAT;>U<
M;7/;MK+^WE^!D\YITKF2(MEY:20W<^27.&YB.\?V23+]<@8D(1$U2; *5G]
M]??9!2A1LNO>MFGS
K')'XIN
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MG_ (#HAXPT1L,F.'7_?YG]$\U97JNE+&:EA:U9U;67I>YGZOD
\V>FE-Z?.,A_Z4'0#*G-70^%<[&W]_#+X/^X.GV
MTZ?/OOMOO_=3.;TG9%;=_"'PY<6S-=B"D@<=VWY:LO*01/Y*_F-(5-E-)?EU
MM?"K#S:T8&SA$W['V7_S]>!)?]0^];]_CW_2$/ZL",X.#@].WN\>G8KSRJIB
M6J6J<&+72)L(,Q'[VJJX,M:)N:Y2,2Y+HXN*_3^^'EHU%7O0\ZG)](UB;+L$
M^/DG3_^Y:<4?4ON_7-VY:8
1S2B^",L?AB.QO44
M859L/>YXP/#-UU=;_<'V2*R4G$'"@Q/I$OGS4)P=GKS_5E0FD0LAB\+41:P2
M 1,0\A9%QP2AJYN,I"/49*(8.XD-9GKB'1E07F>5+C,EZA(@"3L2L:QDMG"@
M)V-KG&/2"!H05"6G2I2Z5!G"#"U4&MHIX9Z)M@ZZ420B4OB%PA*%*#%5&(D-
M0+):@9]CVUOQ_1.VY'A[GG7I6I+!@9320A^QNTB!.0A!3#,3834\Y
2 ;D84@7%
%D;L*24I5P?*8TA\BN#4 021=5E7:TCXFUN0KN[W3
M[2](MWV,BD?CMB]FH.@CP4W.K=/RX>1TB9HN:B@7S0@.4\=PEW&LG".?6F:(
M;Z1*I37TCKPI'#6E]BUG"L=?J D188V3Y/@1K,BR) PEUU?$A(LU1:&)CN&^
M$9IT++-..T:P P]^'<*_5)7SX:#23G7\CI.1<%(G8@^LX1R+M3 �C2
M26/*>ZE6$W%PI>*:@^KI!*LJ2UPLI=43C0PY2D=D,<[S'NG"AQ2,GRQK!D1X
M):0E8Q"$) >39?0U0&%A:KN*EG/$Q&0FR4KI?3M*(RS![V@3HI<_$!XU-_:2
MQ!U3'42)3$]4-TYE,:7CJ.@ER1
^80OSR>\4QP&IJ2JDSHC)?(1:QEM2"6@IMI"C6-5DJY#P4-\
MXV$YAF%!FDX+6!WY>AD1:YG0!1/)E"2E2G79081RE#9T@D+GN?81-I6PPU1E
M)0725);K#J1*K:FG*
%[YK!-Q!"IT4JVA1B>L(&Z:T:&YA(P.Z %#NTI1D9FH2U,@80\#0R
M!JHOVOM_Q^9?7-)J>4NL.6UJ77"TT!Q P@]5,X4#"9Z6D"Y)8U)7\*P;GNX5
MO,DQO M@QEXJM05IVNE=6/^23?A(R!S!5R%^)V1RE(*M].Y^DT0F->.\*M44
M*6/-BDJ*AC!5.*AC+H-M5Y!"HY^-U6TH6AL>KX+C"EUPGH:P%64>#LN6W8NF
M
)ZVIJK1,<8[GKB
M"''/7-(6YR09R(P"*-%D#EK9*WDW62#ZLE^"Z>
?LM\%TR_1$M=*%-J7/UZ8&JF7944X)A4B]7HC;55X;#E.-/>XZESL!1Q[
MO-2TCL_?J(+!B@>ES@-VA*("C6?&J2P83+M
(G8CQ1'3=G&PU/*-Y9BX-A7^M'TM;1Z1G W
M9NO3:EG>6E; D +7V!E_PH2I,@ Z)0 _G, IL4TG%0,(^-2'7&,,.$1
PE@8W*S"&3"+,\+*+#^W&1
M*Z]D7,=\B9$E:T2T-A T3,1KVW89CHGJ(L[J!$P=(
FHW6D6Z(-Q :;6MN,<^6O\
MDOYU"7_
<(#2%@1N;;2#;Y6QKHT9G"5A0/*'R/$42>$7*
M[UPG!%>B>G;XOKO5WUIF:DL:W"^LXY3:!,C7((J(V
)\92;2,P$OL.3*EK-(%,8.SR3(9$>:A0_$=_"AZJP/L
MH14&6X,'<:9RG3CC&9%%P\BO+'W\YEP<':TH# :WC.MX\$3@T&-*SC*9E1-=
MEF#K/-7%0E[65(0R-;Q1PA6@92F42S^1 L9@ZBKQL]M)-!UVDXFV3Z%* <4#
MR*#G$P-<46EW7_QX^AK3SX_'?]#"9E0S!@0*[L350%DMLWO:VW[ZY_.TIX]&
M']\!]-8D'3JWTP9%K?>;_5F1(JQ,FRK?5.WV[Q&AU_"Y$XDB#T'V2TH$%C.?
M*D$#E$&>T$.VAO>&T?P2F7="447,-"+'K7
)
M[!
OKJZ.10
MG%^,+PZ.#TXNSC^^YA'*N$@YG:5\#RB0C7N9K'[S]?:C42@)=JD^2-X<(;M2
M/K?G[QP70@4^M#W(C9S['$9L/1TW]7:\JBT )RB/8XY5@V?;VQWNS>?4E4]\
M@%Q.'1S<,/7@*CBV%8U';1K<57&JQ2=EX[Q!@"BX/37I<'X>5Z%+:;%C]IM-
M)8BZ/_"P5F;90LBX*:8D(EI0M2EQOO $0<[4@OHC5,HD5\H-"&I.T*K<-ZSH
M2H^C3D5*/++$F(F9"N+C_^9RT7ZD=FC[F9P_//#:E*;;V7XG\2K6Y<9() 5U
MOO8&APMS:;]A"21K:[*(UE>LL[4AU-Y>>V["S]I+2U7F-4).J
M^&>JLRP$$(1NRGD3+TY_$OZSTS :9N3YNOP7'3[=>UMU+S]RN=!!&&H?)(;
M4F4*L]0B**:NLQ:4PVD;8! 9+L,W?7E@)LV%FMBXT%:.I4O%)#/SW@:2CGR3
M@G7V%FZI-X ?S8V
!$:FZ$(6!D;-@8UH8T%/J"%B5ZMZME:F4("/<],&4J!W,O/,OKI
MQ3J1_I;KBK=@&XZ-4):PK9(.7@E?.N9$1MNXSB$:,(Q3?FGFU WD@BH3!
>)+>E&DE_FU5UH?$Z>]=
MZE6+:,R*JUD@J[\XV6OTS"= X6PQY'1I?GX-I^*EFUA+5HJ"M.),\55&T'E!
MQS_H=U\MTRBJU@N.(6(?R0L?[?: +Y(^7C;D2[JVEH4MTJDW4KM]^7_72($
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M_M7.0_X_Y/PO4$L! A0#% @ (J<9793%T/>F%P ><( !$
M ( ! ')G;G@M,C R-C X,C4N:'1M4$L! A0#% @ (J<972^#
M &"L" N6$ !$ ( !U1< ')G;G@M,C R-C X,C4N>'-D
M4$L! A0#% @ (J<97
XML
14
rgnx-20260825_htm.xml
IDEA: XBRL DOCUMENT
0001590877
2026-08-25
2026-08-25
0001590877
false
8-K
2026-08-25
REGENXBIO Inc.
DE
001-37553
47-1851754
9804 Medical Center Drive
Rockville
MD
20850
240
552-8181
N/A
false
false
false
false
Common Stock, par value $0.0001 per share
RGNX
NASDAQ
false